The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: One size does not fit all

Gil Y. Melmed, Brennan M. Spiegel, Brian Bressler, Adam S. Cheifetz, Shane M. Devlin, Laura E. Harrell, Peter M. Irving, Jennifer Jones, Gilaad G. Kaplan, Patricia L. Kozuch, Fernando S. Velayos, Leonard Baidoo, Miles P. Sparrow, Corey A. Siegel

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Background & Aims: There is no consensus on the appropriateness of concomitant immunomodulators with anti-tumor necrosis factor (TNF) therapy for Crohn's disease. Some patients benefit from concomitant immunomodulators, but concerns related to infections and lymphoma risk have dampened enthusiasm for this approach. We applied the RAND/University of California Los Angeles Appropriateness Method toward establishing appropriateness of concomitant immunomodulators and anti-TNF therapies for Crohn's disease. Methods: A literature review was conducted regarding efficacy and safety of concomitant immunomodulators in the setting of anti-TNF therapy for Crohn's disease and presented to the Building Research in Inflammatory Bowel Disease Globally group, a globally diverse panel of 13 gastroenterologists clinically experienced in inflammatory bowel disease. A total of 134 scenarios were constructed using several clinical variables. Panelists used a modified Delphi method to rate the appropriateness of concomitant immunomodulators, and met to discuss and re-rate appropriateness. Disagreement was assessed using a validated index. Results: Concomitant immunomodulators were generally rated appropriate for 63 scenarios, uncertain for 60 scenarios, and inappropriate for 11 scenarios. In general, concomitant immunomodulators were appropriate for those with extensive disease, shorter duration of disease, perianal involvement, prior surgery, females, and older patients (>26 y). Concomitant immunomodulators were generally rated inappropriate for young males, and in some scenarios involving uncomplicated disease. Smoking and the particular anti-TNF medication did not influence ratings. Disagreement was observed in 6 of 134 scenarios. Conclusions: The appropriateness of concomitant immunomodulators with anti-TNF therapy for Crohn's disease was determined through a modified Delphi panel approach based on expert interpretation of the available literature. Clinicians should consider multiple factors when considering concomitant immunomodulators with anti-TNF treatment.

Original languageEnglish (US)
Pages (from-to)655-659
Number of pages5
JournalClinical Gastroenterology and Hepatology
Volume8
Issue number8
DOIs
StatePublished - Aug 1 2010

Keywords

  • Adalimumab
  • Anti-Tumor Necrosis α Therapy
  • Certolizumab
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Infliximab

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: One size does not fit all'. Together they form a unique fingerprint.

  • Cite this

    Melmed, G. Y., Spiegel, B. M., Bressler, B., Cheifetz, A. S., Devlin, S. M., Harrell, L. E., Irving, P. M., Jones, J., Kaplan, G. G., Kozuch, P. L., Velayos, F. S., Baidoo, L., Sparrow, M. P., & Siegel, C. A. (2010). The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: One size does not fit all. Clinical Gastroenterology and Hepatology, 8(8), 655-659. https://doi.org/10.1016/j.cgh.2010.04.023